Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 8/20 | 0.51 |
| ▸ | GSK3B | P49841 | 8/20 | 0.51 |
| ▸ | FLT3 | P36888 | 7/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.49 |
| ▸ | JAK2 | O60674 | 6/20 | 0.49 |
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.49 |
| ▸ | PRKACA | P17612 | 3/20 | 0.49 |
| ▸ | PLK1 | P53350 | 4/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16760739 | 1.00 | GSK3A (0.51) | GSK3AGSK3BFLT3PIK3CGJAK2 | |
| SCHEMBL16760751 | 0.92 | — | — | |
| SCHEMBL14685274 | 0.92 | — | — | |
| SCHEMBL14677776 | 0.89 | GSK3A (0.52) | GSK3AGSK3BFLT3PIK3CGJAK2 | |
| SCHEMBL14677770 | 0.89 | GSK3A (0.52) | GSK3AGSK3BFLT3PIK3CGJAK2 | |
| SCHEMBL14678022 | 0.88 | GSK3A (0.54) | GSK3AGSK3BFLT3PIK3CGJAK2 | |
| SCHEMBL14685077 | 0.88 | GSK3A (0.54) | GSK3AGSK3BFLT3PIK3CGJAK2 | |
| SCHEMBL14685103 | 0.88 | GSK3A (0.55) | GSK3AGSK3BFLT3PIK3CGJAK2 | |
| SCHEMBL14678403 | 0.88 | GSK3A (0.55) | GSK3AGSK3BFLT3PIK3CGJAK2 | |
| SCHEMBL16760766 | 0.88 | GSK3A (0.54) | GSK3AGSK3BFLT3PIK3CGJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875855-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3147284-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3147284-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20180155342-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2018-06-07 | — | — | US | disclosed |
| US-9908878-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3147284-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2739623-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2017-01-11 | — | — | EP | disclosed |
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-9394302-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150191468-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| US-9051319-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | GSK3A 997/4885GSK3B 924/4885FLT3 845/4885 |
| US-20150191468-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | GSK3A 997/4885GSK3B 924/4885FLT3 845/4885 |
| US-10875855-B2 | Inhibitors of influenza viruses replication | ACE, RNASEH1, ACE2 | GSK3A 997/4885GSK3B 924/4885FLT3 845/4885 |
| US-20180155342-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | GSK3A 997/4885GSK3B 924/4885FLT3 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.